435 related articles for article (PubMed ID: 22315431)
1. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.
Wei W; Dutchak PA; Wang X; Ding X; Wang X; Bookout AL; Goetz R; Mohammadi M; Gerard RD; Dechow PC; Mangelsdorf DJ; Kliewer SA; Wan Y
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3143-8. PubMed ID: 22315431
[TBL] [Abstract][Full Text] [Related]
2. FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists.
Li X; Stanislaus S; Asuncion F; Niu QT; Chinookoswong N; Villasenor K; Wang J; Wong P; Boyce R; Dwyer D; Han CY; Chen MM; Liu B; Stolina M; Ke HZ; Ominsky MS; Véniant MM; Xu J
J Bone Miner Res; 2017 Apr; 32(4):834-845. PubMed ID: 27505721
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.
Dutchak PA; Katafuchi T; Bookout AL; Choi JH; Yu RT; Mangelsdorf DJ; Kliewer SA
Cell; 2012 Feb; 148(3):556-67. PubMed ID: 22304921
[TBL] [Abstract][Full Text] [Related]
4. Spinal cord injury causes bone loss through peroxisome proliferator-activated receptor-γ and Wnt signalling.
Yan J; Li B; Chen JW; Jiang SD; Jiang LS
J Cell Mol Med; 2012 Dec; 16(12):2968-77. PubMed ID: 22947224
[TBL] [Abstract][Full Text] [Related]
5. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Patel JJ; Butters OR; Arnett TR
Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887
[TBL] [Abstract][Full Text] [Related]
6. Growth differentiation factor 11 is a protective factor for osteoblastogenesis by targeting PPARgamma.
Zhang Y; Shao J; Wang Z; Yang T; Liu S; Liu Y; Fan X; Ye W
Gene; 2015 Feb; 557(2):209-14. PubMed ID: 25534870
[TBL] [Abstract][Full Text] [Related]
7. Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2).
Stechschulte LA; Ge C; Hinds TD; Sanchez ER; Franceschi RT; Lecka-Czernik B
J Biol Chem; 2016 Nov; 291(47):24475-24486. PubMed ID: 27687725
[TBL] [Abstract][Full Text] [Related]
8. Deletion of phospholipase D1 decreases bone mass and increases fat mass via modulation of Runx2, β-catenin-osteoprotegerin, PPAR-γ and C/EBPα signaling axis.
Kang DW; Hwang WC; Noh YN; Che X; Lee SH; Jang Y; Choi KY; Choi JY; Min DS
Biochim Biophys Acta Mol Basis Dis; 2021 May; 1867(5):166084. PubMed ID: 33497821
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL
Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153
[TBL] [Abstract][Full Text] [Related]
10. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA
Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917
[TBL] [Abstract][Full Text] [Related]
11. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone.
Bruedigam C; Eijken M; Koedam M; van de Peppel J; Drabek K; Chiba H; van Leeuwen JP
Stem Cells; 2010 May; 28(5):916-27. PubMed ID: 20213769
[TBL] [Abstract][Full Text] [Related]
12. The Transcriptional Modulator Interferon-Related Developmental Regulator 1 in Osteoblasts Suppresses Bone Formation and Promotes Bone Resorption.
Iezaki T; Onishi Y; Ozaki K; Fukasawa K; Takahata Y; Nakamura Y; Fujikawa K; Takarada T; Yoneda Y; Yamashita Y; Shioi G; Hinoi E
J Bone Miner Res; 2016 Mar; 31(3):573-84. PubMed ID: 26391411
[TBL] [Abstract][Full Text] [Related]
13. A Liver-Bone Endocrine Relay by IGFBP1 Promotes Osteoclastogenesis and Mediates FGF21-Induced Bone Resorption.
Wang X; Wei W; Krzeszinski JY; Wang Y; Wan Y
Cell Metab; 2015 Nov; 22(5):811-24. PubMed ID: 26456333
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.
Lazarenko OP; Rzonca SO; Hogue WR; Swain FL; Suva LJ; Lecka-Czernik B
Endocrinology; 2007 Jun; 148(6):2669-80. PubMed ID: 17332064
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms of PPAR-γ Governing MSC Osteogenic and Adipogenic Differentiation.
Zhuang H; Zhang X; Zhu C; Tang X; Yu F; Shang GW; Cai X
Curr Stem Cell Res Ther; 2016; 11(3):255-64. PubMed ID: 26027680
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone decreases bone mass and bone marrow fat.
Harsløf T; Wamberg L; Møller L; Stødkilde-Jørgensen H; Ringgaard S; Pedersen SB; Langdahl BL
J Clin Endocrinol Metab; 2011 May; 96(5):1541-8. PubMed ID: 21367933
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
18. High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling.
So WY; Cheng Q; Chen L; Evans-Molina C; Xu A; Lam KS; Leung PS
Diabetes; 2013 Nov; 62(11):3751-9. PubMed ID: 23897951
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
[TBL] [Abstract][Full Text] [Related]
20. Feeding blueberry diets to young rats dose-dependently inhibits bone resorption through suppression of RANKL in stromal cells.
Zhang J; Lazarenko OP; Kang J; Blackburn ML; Ronis MJ; Badger TM; Chen JR
PLoS One; 2013; 8(8):e70438. PubMed ID: 23936431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
